Direct costs of occupational asthma in Quebec between 1988 and 2002

Jean-Luc Malo MD, Jocelyne L’Archevêque RT, Heberto Ghezzo PhD

BACKGROUND: Forty to 70 cases of occupational asthma due to sensitization to an agent present in the workplace are accepted each year by the Commission de la santé et de la sécurité du travail, the Quebec medicolegal agency.

OBJECTIVES AND METHODS: In a random sample of eight to 10 accepted claims per year from 1988 to 2002, the direct costs of compensation for loss of income (CLI) and compensation for functional impairment (CFI), as well as the associations of these costs with selected variables, were assessed.

RESULTS: Mean costs (presented as Canadian dollars \times 10^3) of CLI, CFI and total were 72.5, 11.7 and 92.8, respectively, while the median costs were 40.7, 7.6 and 61.3 for CLI, CFI and total, respectively. Median CLI costs were significantly higher in men than women (69.9 versus 13.1), workers aged 40 years or older versus those younger than 40 years (90.1 versus 27.4), workers with occupational asthma due to workplace exposure to low versus high molecular weight agents (51.2 versus 38.6), and workers taking inhaled steroids at diagnosis (92 versus 52) and reassessment (81 versus 35). Median CFI costs were significantly higher for individuals being treated with inhaled steroids at the time of diagnosis (61.8) than workers who stayed with the same employer but in a different job (5.4). Median CFI costs were significantly higher for individuals being treated with inhaled steroids at the time of diagnosis (14.0 versus 5.2) and reassessment (13 versus 6), and for those left with bronchial hyperresponsiveness (9.5 versus 0.8) related to forced expiratory volume in 1 s and forced expiratory volume in 1 s/forced vital capacity.

CONCLUSION: Age, sex, nature of occupational agent, treatment with inhaled steroids and type of rehabilitation all affect CLI, whereas lung function status at baseline and reassessment is related to CFI.

Key Words: Asthma in the workplace; Costs; Occupational asthma

The cost of OA in terms of compensation for loss of income (CLI) and compensation for functional impairment (CFI) was previously assessed for workers compensated by the Commission de la santé et de la sécurité du travail (CSST) of Quebec, for the years 1986 to 1988 (3). During this period, the mean total cost for each case was found to be approximately $50,000. CLI mainly includes compensation for lost salary (90% of salary) during the readaptation period after the worker starts being no longer exposed to the causal agent (up to two years). CFI corresponds to a lump sum allocated at the time the worker is reassessed for disability two years after diagnosis and removal from exposure. This allocation is based on the percentage of disability and age. Total cost primarily consists of CLI and CFI, although asthma medication costs and professional fees are also covered by the CSST from the time of diagnosis for life. After

Axe de recherche en santé respiratoire, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec
Correspondence: Dr Jean-Luc Malo, Department of Chest Medicine, Hôpital du Sacré-Cœur de Montréal, 5400 West Gouin Boulevard, Montreal, Quebec H4J 1C5. Telephone 514-338-2796, fax 514-338-3123, e-mail maloj@meddir.umontreal.ca

©2008 Pulsus Group Inc. All rights reserved

Can Respir J Vol 15 No 8 November/December 2008

413
age 55 years, workers are offered permanent CLI until 65 years of age. With regard to CFI, the CSST medical boards use a scale based on airway calibre and responsiveness, as well as on the severity of asthma as reflected by the need for inhaled steroids (2).

We wanted to re-examine these costs over a more prolonged period, more likely to reflect economic cycles, and relate these costs to anthropometric, clinical and functional variables at the time of diagnosis and reassessment, which is generally carried out two years after diagnosis.

SUBJECTS AND METHODS
The Quebec CSST was contacted to obtain information for a random selection of 10 subjects per year who received compensation for OA on a yearly basis between 1988 and 2002, inclusively. After examining files, key information related to costs or diagnosis (possible cases of OA without a latency period) was found to be missing in a few instances. Therefore, depending on the year, eight to 10 subjects with OA were retained. In the other instances, although there might have been missing data, these were not considered crucial. The following information was collected:

• costs for CLI and CFI as well as total cost;
• sex and age;
• CSST regional offices categorized into three regions: the Montreal area, the Quebec City area and the rest of Quebec;
• type of agent causing OA, classified as either high or low molecular weight agents;
• inhaled steroids at the time of diagnosis and reassessment;
• functional variables at the time of diagnosis and reassessment: forced expiratory volume in 1 s (FEV₁), FEV₁/FVC forced vital capacity, and provocative concentration of methacholine causing a 20% fall in FEV₁;
• type of CLI in the first two years after diagnosis: return to work for the same employer in a different job, work for a different employer without a training program, work for a different employer with a training program, retired and unemployed; and
• proportion of permanent disability that was allocated at the time of reassessment according to a scale (2).

The protocol was accepted by the CSST and the Ethics Committee at Hôpital du Sacré-Coeur de Montréal (Montreal, Quebec).

Statistical analysis
Because data were not normally distributed, the Kruskal-Wallis rank sum test was used for all comparisons. Regression analysis was also used to relate costs to functional variables. All analyses were performed with SPSS 14.0 for Windows (Statistical Products and Service Solution, USA) and S-Plus 2000. P<0.05 was considered to be statistically significant.

RESULTS
A total of 140 claims were kept for analysis in the 15-year period (eight to 10 claims per year). The mean (± SD) costs (presented as Canadian dollars ×10³) for CLI, CFI and total were 72.5±78,

11.7±12 and 92.8±86, respectively, while median costs were 40.7, 7.6 and 61.3 for CLI, CFI and total, respectively.

Table 1 presents the associations of these costs with selected anthropometric, administrative, clinical and functional variables. The mean costs for CLI were higher for men than women, and higher for workers aged 40 years or older than those younger than 40 years of age. Costs for the two largest urban areas (Montreal and Quebec City) did not vary versus the rest of Quebec. Costs for CLI and total costs were higher for those who had retired (aged 55 years or older) or were still unemployed at the time of reassessment. CLI and total costs were higher for cases of asthma caused by low molecular weight agents (n=73, including 25 workers with OA due to isocyanates) versus high molecular weight agents (n=51).

All costs were higher for workers with more severe asthma, as reflected by the need for inhaled steroids at the time of diagnosis and reassessment. Although only significantly higher in the case of CLI, costs of CLI and CFI were higher for subjects with abnormal FEV₁ values at diagnosis and reassessment. Similar findings were obtained by examining FEV₁/FVC values (results not shown). CFI costs were also higher for workers with significant bronchial hyperresponsiveness (all workers had significant bronchial hyperresponsiveness at the time of diagnosis). CFI cost was directly related to the proportion of permanent impairment that was allocated (r²=0.81). FEV₁ in per cent predicted both at diagnosis (r²=0.35) and reassessment (r²=0.42) was significantly related to CFI costs. Significant correlations were also found using the ratio FEV₁/FVC in per cent predicted (r²=0.29 at diagnosis and r²=0.47 at reassessment).

Table 2 presents the median values with distribution of quantile values for all indexes that were significant according to Table 1. For age and sex, differences up to the 25th percentile are minimal, while they become more apparent at higher percentiles. With regard to the type of readaptation, the costs for working for a different employer, with or without retraining, were distributed in a proportional way along the scale, whereas the costs for those who retired were proportionally higher for the 25% and 50% quantiles. For the type of occupational agent, the situation is different; the cost of the most severe cases are equally expensive, while for mildly and moderately severe cases, the cost of OA due to low molecular weight agents is greater than that for high molecular weight agents.

DISCUSSION
Our study shows a significant increase in direct compensation costs for OA with a latency period, in Quebec. For the period between 1988 and 2002, the mean total cost (CDN$×10³) was 93±86, whereas the mean total cost between 1986 and 1988 was 49 (range 2.1 to 330.9) (3). The increase principally affected CLI, and CFI costs declined. Part of the increase in CLI and total costs is related to inflation (approximately 2% per year in Canada). Our study did not include all cases of OA accepted by the Quebec CSST between 1988 and 2002 – our study is based on a random sample. However, we have no reason to believe that this sample is not representative of the whole population. The advantage of selecting such a sample is that the identification of cases is more precise, which allowed us to relate costs to selected variables.
Cost of occupational asthma in Quebec

TABLE 1

Association of costs with anthropometric, administrative, clinical and functional variables

|                          | Compensation for loss of income, CDN×$10^3 | Compensation for functional impairment, CDN×$10^3 | Total cost, CDN×$10^3 |
|--------------------------|---------------------------------------------|---------------------------------------------------|------------------------|
| **Sex**                  |                                             |                                                   |                        |
| Men (n=94)               | 87±86                                       | 12±12                                            | 133±105                |
| Women (n=36)             | 34±34***                                    | 11±10                                            | 77±61***               |
| **Age, years**           |                                             |                                                   |                        |
| <40 (n=64)               | 47±49                                       | 10±6                                             | 89±78                  |
| ≥40 (n=66)               | 97±94***                                    | 13±9                                             | 144±108***             |
| **Administrative area**  |                                             |                                                   |                        |
| Montreal (n=70)          | 72±92                                       | 12±12                                            | 113±107                |
| Quebec City (n=16)       | 85±70                                       | 11±8                                             | 136±69                 |
| Other (n=44)             | 69±58                                       | 12±12                                            | 119±92                 |
| **Type of rehabilitation program at assessment** | | | |
| Working for the same employer (n=23) | 43±86                                       | 10±9                                             | 72±93                  |
| Working for a different employer (n=27) | 35±27                                       | 11±10                                            | 83±41                  |
| Working for a different employer with retraining (n=8) | 32±33                                       | 6±4                                              | 69±53                  |
| Retired (n=19)           | 138±75                                      | 18±14                                            | 194±86                 |
| Unemployed (n=36)        | 100±86                                      | 16±13                                            | 159±111                |
| Not reassessed (n=13)    | 48±50***                                    | 2±0.7                                            | 73±66***               |
| **Occupational agent**   |                                             |                                                   |                        |
| Low molecular weight (n=73) | 80±73                                      | 11±11                                            | 128±69                 |
| High molecular weight (n=51) | 53±63*                                     | 12±11                                            | 94±86*                 |
| **Inhaled steroids at diagnosis** |                                              |                                                   |                        |
| Present (n=57)           | 95±90                                       | 14±14                                            | 127±99                 |
| Absent (n=48)            | 54±61**                                     | 10±8**                                           | 78±65**                |
| **Inhaled steroids at reassessment** |                                             |                                                   |                        |
| Present (n=52)           | 109±91                                      | 19±14                                            | 118±97                 |
| Absent (n=53)            | 44±53***                                    | 8±6***                                           | 64±57***               |
| **FEV₁ at diagnosis , % predicted** |                                             |                                                   |                        |
| <80 (n=43)               | 86±77                                       | 20±15                                            | 152±97                 |
| ≥80 (n=81)               | 67±81                                       | 8±7*                                             | 103±97                 |
| **FEV₁ at reassessment, % predicted** |                                             |                                                   |                        |
| <80 (n=28)               | 93±96                                       | 21±13                                            | 175±115                |
| ≥80 (n=55)               | 69±73                                       | 9±7**                                            | 104±80                 |
| **PC₂₀ at reassessment, mg/mL** |                                             |                                                   |                        |
| <16 (n=83)               | 79±80                                       | 16±11                                            | 137±102                |
| ≥16 (n=26)               | 68±82                                       | 5±9***                                           | 90±90*                 |

Values are presented as the mean ± SD. *P≤0.05; **P≤0.01; ***P≤0.001 by nonparametric statistics (Kruskal-Wallis test). FEV₁ Forced expiratory volume in 1 s; PC₂₀ Provocative concentration of methacholine causing a 20% fall in FEV₁.

Direct costs were higher for older subjects, who were also the ones who took early retirement with compensation for CLI between 55 and 65 years of age. Costs were also higher for men than for women due to CLI that covers salary loss, which is likely to be higher for men. CLI covers the cost of salary loss for a period of one to two years after diagnosis, after which a worker is compensated whenever he or she has to be away from work because of an exacerbation of asthma. Men were significantly older than women at diagnosis (42 versus 36 years of age), which can also explain the higher costs for men. In the present sample, a significant proportion of workers (27.7%) were still unemployed at the time of reassessment, which may contribute to higher costs. The proportion of unemployed workers at the time of reassessment in the present study is slightly higher than that in a sample of 40 cases who underwent reassessment two years after diagnosis in a recent study by our group (18%) (4).

The cost of CLI was not related to the administrative area, suggesting that it is no more difficult to relocate workers with OA from large urban areas versus those from rural areas. CLI programs were more costly in workers with OA due to exposure to low molecular weight agents. In some instances, it is likely that the agent per se plays a role because it may be more difficult to relocate a worker if the responsible agent is present throughout the workplace. However, it is also possible that workers with OA due to exposure to isocyanates, which represents approximately one-third of cases of OA due to low molecular weight agents, are more difficult to relocate.

The severity of asthma in terms of the need for inhaled steroids at diagnosis and reassessment influenced costs not only in terms of CFI, as expected, but also with regard to CLI. Workers with more severe asthma might therefore be more difficult to relocate to a different job. As expected, airway calibre and hyperresponsiveness at the time of reassessment influenced CLI costs.

Only the principal direct costs were considered in the current study. Other direct costs include professional fees and the
TABLE 2
Distribution of costs for compensations for loss of income and functional impairment

| Compensation for loss of income, CDN$×10^3 | Quantiles |
|-------------------------------------------|-----------|
| Sex                                       | Median    |
| Women                                     | 13.1      |
| Men                                       | 69.9      |
| Age, years                                |           |
| <40                                       | 27.4      |
| ≥40                                       | 90.1      |
| Type of readaptation                      |           |
| Working for the same employer             | 5.4       |
| Working for a different employer          | 19.4      |
| Working for a different employer with retraining | 10.4   |
| Retired                                   | 61.8      |
| Unemployed                                | 71.2      |
| Working for the same employer             |           |
| Low molecular weight                      | 51.2      |
| High molecular weight                     | 38.6      |

Compensation for functional impairment, CDN$×10^3

| Inhaled steroids at the time of diagnosis | FEV1 at reassessment, % predicted | PC20 at reassessment, mg/mL |
|------------------------------------------|----------------------------------|-----------------------------|
| Present                                  | 14.0                             | 11.4                        |
| Absent                                   | 5.2                              | 6.9                         |
| <80                                      | 2.5                              | 1.5                         |
| ≥80                                      | 2.3                              | 2.3                         |
| <16                                      | 9.5                              | 6.9                         |
| ≥16                                      | 9.5                              | 1.5                         |

ACKNOWLEDGEMENTS: The authors sincerely thank Dr Daniel Boucher and Mélanie Vincent, Esq, of the Commission de la santé et de la sécurité du travail du Québec for allowing access to relevant data and providing helpful suggestions. They also express their gratitude to Kathe Lieber for copy-editing this manuscript.

SUPPORT: This study was supported by the Centre for Asthma in the Workplace, Canadian Institutes for Health Research, the Canadian and Quebec Lung Associations, and the Institut de recherche Robert-Sauvé en santé et sécurité du travail du Québec.

REFERENCES
1. Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI. Asthma in the Workplace, 3rd edn. New York: Taylor & Francis, 2006.
2. Bernstein IL, Keskinen H, Blanc PD, Chan-Yeung M, Malo JL. Medicolegal aspects, compensation aspects, and evaluation of impairment/disability. In: Asthma in the Workplace. Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI, eds. New York: Taylor & Francis, 2006:319-51.
3. Dewitte JD, Chan-Yeung M, Malo JL. Medicolegal and compensation aspects of occupational asthma. Eur Respir J 1994;7:969-80.
4. Yacoub MR, Lavoie K, Lacoste G, et al. Assessment of impairment/disability due to occupational asthma through a multidimensional approach. Eur Respir J 2007;29:889-96.
5. Poonai N, van Diepen S, Bharatha A, Manduch M, Deklaj T, Tarlo SM. Barriers to diagnosis of occupational asthma in Ontario. Can J Public Health 2005;96:230-3.
6. Vandenplas O, Toren K, Blanc PD. Health and socioeconomic impact of work-related asthma. Eur Respir J 2003;22:689-97.